2015 News Releases

2015 News Releases

Webcast ImageWebcast
Pacira Pharmaceuticals, Inc. at the BMO Capital Markets Conference Presentation (Replay)
12/12/18 at 1:20 p.m. ET
Pacira Pharmaceuticals, Inc. at the BMO Capital Markets Conference Presentation
Wednesday, December 12, 2018 1:20 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Pacira Pharmaceuticals, Inc. to Present at the 34th Annual J.P. Morgan Healthcare Conference
12/28/15
Pacira Pharmaceuticals Announces Favorable Resolution With U.S. Food and Drug Administration, Which Reaffirms the Broad Indication for EXPAREL®
12/15/15
Pacira Pharmaceuticals, Inc. to Present at the 27th Annual Piper Jaffray Healthcare Conference
11/24/15
New Survey Sheds Light on Prescription Drug Use Among Women After Surgery in the United States
11/17/15
Pacira Pharmaceuticals, Inc. to Present at the Jefferies Autumn 2015 Global Healthcare Conference
11/11/15
New Study Finds Decreased Opioid Use, Hospital Stay and Readmission Rates With EXPAREL Following Knee Replacement Surgery
11/06/15
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial Results
10/27/15
Pacira Pharmaceuticals Announces the Promotion of James S. Scibetta to President
10/20/15
Pacira Pharmaceuticals Announces Timing for Third Quarter 2015 Financial Results Webcast and Conference Call
10/13/15
Pacira Pharmaceuticals Seeks Court Injunction to Defend its Rights to Share Information about EXPAREL® Consistent with its FDA-Approved Indication
09/08/15
Pacira Pharmaceuticals Appoints James B. Jones, MD, PharmD, as Senior Vice President and Chief Medical Officer
08/19/15
Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in August
08/03/15
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results
07/30/15
Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results for Controlling Postsurgical Pain in Dogs
07/15/15
Pacira Pharmaceuticals Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call
07/14/15
Pacira Pharmaceuticals Appoints Scott Braunstein, MD, to Oversee Strategy and Corporate Development
07/14/15
Pacira Pharmaceuticals Announces Completion of End-of-Review Process with FDA Regarding EXPAREL sNDA for Nerve Block
05/28/15
Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in June
05/20/15
Pacira Announces New Data Supporting Clinical and Pharmacoeconomic Utility of EXPAREL in Patients Undergoing Various Surgical Procedures
05/19/15
Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
05/07/15
Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenues of $56.0 Million and First Quarter 2015 Financial Results
04/30/15
Pacira Receives Subpoena from the U.S. Department of Justice
04/16/15
Pacira Pharmaceuticals Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call
04/13/15
Pacira Announces New Data on Health Economic Benefits of EXPAREL for Postsurgical Pain Control Following Total Knee Replacement Surgery
04/10/15
Pacira Announces Data Reinforcing Benefits of EXPAREL® for Postsurgical Pain Control Following Total Hip and Knee Replacement Surgery
03/26/15
New Data Demonstrate Reduced Opioid Requirements Following Use of EXPAREL in Hysterectomy and Mastectomy Procedures
03/23/15
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
03/04/15
Pacira Receives Complete Response Letter from FDA for sNDA Seeking Approval of EXPAREL® Use in Nerve Block to Provide Postsurgical Analgesia
03/02/15
Pacira Pharmaceuticals, Inc. Reports 2014 Financial Results
02/24/15
Pacira Pharmaceuticals, Inc. Announces Resolution of Warning Letter with FDA’s Office of Prescription Drug Promotion
02/11/15
Pacira Pharmaceuticals Announces Timing for 2014 Financial Results Webcast and Conference Call
02/10/15
Pacira Pharmaceuticals, Inc. to Host Analyst & Investor Day on Jan. 22 in New York
01/08/15
Pacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue of $61.8 Million and Estimated Full-Year Total Revenue of $197.7 Million
01/08/15